A new targeted breast cancer drug can increase the survival time of some hard-to-treat patients by almost six months, research has shown.
T-DM1 combines the antibody drug Herceptin with a powerful chemotherapy agent.
The treatment, which is only suitable for breast cancer patients with a defective Her2 gene, is designed to penetrate cancer cells and destroy them from within. Because its action is so precise, a normally toxic form of chemotherapy can be used with few side-effects.
We moderate all comments on HeraldScotland on either a pre-moderated or post-moderated basis. If you're a relatively new user then your comments will be reviewed before publication and if we know you well then your comments will be subject to moderation only if other users or the moderators believe you've broken the rules, which are available here.
Moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours. Please be patient if your posts are not approved instantly.
